IO Therapeutics, Inc.;The Johns Hopkins University
发明人:
申请号：
EP16869301.8
公开号：
EP3380086A4
申请日:
2016.11.23
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RARα) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
